2020
Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation
Yeh YJ, Jenike KM, Calvi RM, Chiarella J, Hoh R, Deeks SG, Ho YC. Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation. Journal Of Clinical Investigation 2020, 130: 4969-4984. PMID: 32573496, PMCID: PMC7456222, DOI: 10.1172/jci137371.Peer-Reviewed Original ResearchConceptsHIV-1 reactivationHIV-1-infected cellsT cell activationImmune activationHIV-1-induced immune activationCell activationHIV-1 RNA transcriptionHIV-1-infected individualsDrug screensEffective antiretroviral therapyHIV-1 transcriptionFilgotinib treatmentImmune exhaustionAntiretroviral therapyCell line modelsCancer-related gene expressionHIV-1 splicingViral antigensT cellsDrug treatmentHigh-throughput drug screensJAK inhibitorsFilgotinibDruggable targetsDrug candidates
2012
Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing
Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St. John E, Moreno E, Kozal M. Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing. PLOS ONE 2012, 7: e30118. PMID: 22355307, PMCID: PMC3280244, DOI: 10.1371/journal.pone.0030118.Peer-Reviewed Original ResearchConceptsPI/rDrug-resistant mutationsVirologic failureUltra-deep sequencingR regimenLow-level resistant variantsMajor PI resistance mutationsPI/r regimenResistant variantsARV-naïve subjectsPI-resistant variantsHIV-positive patientsAtazanavir/ritonavirLopinavir/ritonavirM184V/ILow-level variantsPI resistance mutationsMinority of casesTenofovir/RegimenStanford HIVdbResistance mutationsPhenotypic resistanceResistant mutationsStandard genotyping